355 related articles for article (PubMed ID: 21794114)
1. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI.
Pituskin E; Haykowsky M; Mackey JR; Thompson RB; Ezekowitz J; Koshman S; Oudit G; Chow K; Pagano JJ; Paterson I
BMC Cancer; 2011 Jul; 11():318. PubMed ID: 21794114
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
3. Small benefits in trastuzumab-related cardiotoxicity.
Das M
Lancet Oncol; 2017 Jan; 18(1):e5. PubMed ID: 27956153
[No Abstract] [Full Text] [Related]
4. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
Lynce F; Barac A; Geng X; Dang C; Yu AF; Smith KL; Gallagher C; Pohlmann PR; Nunes R; Herbolsheimer P; Warren R; Srichai MB; Hofmeyer M; Cunningham A; Timothee P; Asch FM; Shajahan-Haq A; Tan MT; Isaacs C; Swain SM
Breast Cancer Res Treat; 2019 Jun; 175(3):595-603. PubMed ID: 30852761
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure.
Armenian SH; Hudson MM; Chen MH; Colan SD; Lindenfeld L; Mills G; Siyahian A; Gelehrter S; Dang H; Hein W; Green DM; Robison LL; Wong FL; Douglas PS; Bhatia S
BMC Cardiovasc Disord; 2016 Oct; 16(1):187. PubMed ID: 27716152
[TBL] [Abstract][Full Text] [Related]
7. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
[TBL] [Abstract][Full Text] [Related]
8. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
Ferrari R;
Arch Intern Med; 2006 Mar; 166(6):659-66. PubMed ID: 16567606
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.
Boekhout AH; Gietema JA; Milojkovic Kerklaan B; van Werkhoven ED; Altena R; Honkoop A; Los M; Smit WM; Nieboer P; Smorenburg CH; Mandigers CM; van der Wouw AJ; Kessels L; van der Velden AW; Ottevanger PB; Smilde T; de Boer J; van Veldhuisen DJ; Kema IP; de Vries EG; Schellens JH
JAMA Oncol; 2016 Aug; 2(8):1030-7. PubMed ID: 27348762
[TBL] [Abstract][Full Text] [Related]
10. Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial.
Kirkham AA; Pituskin E; Thompson RB; Mackey JR; Koshman SL; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Tsui AK; Ezekowitz JA; Oudit GY; Paterson DI
Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):130-139. PubMed ID: 33605416
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial.
Livi L; Barletta G; Martella F; Saieva C; Desideri I; Bacci C; Del Bene MR; Airoldi M; Amoroso D; Coltelli L; Scotti V; Becherini C; Visani L; Salvestrini V; Mariotti M; Pedani F; Bernini M; Sanchez L; Orzalesi L; Nori J; Bianchi S; Olivotto I; Meattini I
JAMA Oncol; 2021 Oct; 7(10):1544-1549. PubMed ID: 34436523
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy.
Cheng S; Wang J; Wang Y; Qi L; Li F; Liu J; Chen J; Fan Y; Xie L
Eur Radiol Exp; 2023 May; 7(1):22. PubMed ID: 37183212
[TBL] [Abstract][Full Text] [Related]
15. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
[TBL] [Abstract][Full Text] [Related]
17. Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
Remme WJ
Cardiol Clin; 2007 Nov; 25(4):581-94; vii. PubMed ID: 18063162
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
[TBL] [Abstract][Full Text] [Related]
19. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.
Gulati G; Heck SL; Ree AH; Hoffmann P; Schulz-Menger J; Fagerland MW; Gravdehaug B; von Knobelsdorff-Brenkenhoff F; Bratland Å; Storås TH; Hagve TA; Røsjø H; Steine K; Geisler J; Omland T
Eur Heart J; 2016 Jun; 37(21):1671-80. PubMed ID: 26903532
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN).
Pituskin E; Haykowsky M; McNeely M; Mackey J; Chua N; Paterson I
BMC Cancer; 2016 Sep; 16(1):733. PubMed ID: 27629548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
